الفرق بين المراجعتين لصفحة: «قالب:مضادات الفيروسات القهقرية المستخدمة ضد فيروس الإيدز»
اذهب إلى التنقل
اذهب إلى البحث
(أنشأ الصفحة ب'{{Navbox | name = Antiretroviral drug | title = Antiviral drugs: antiretroviral drugs used against HIV (primarily J05) |state = {{{state<inclu...') |
كنان الطرح (نقاش | مساهمات) لا ملخص تعديل |
||
(4 مراجعات متوسطة بواسطة 3 مستخدمين غير معروضة) | |||
سطر 2: | سطر 2: | ||
| name = Antiretroviral drug | | name = Antiretroviral drug | ||
| title = [[Antiviral drug]]s: [[antiretroviral drug]]s used against [[HIV]] (primarily [[ATC code J05|J05]]) | | title = [[Antiviral drug]]s: [[antiretroviral drug]]s used against [[HIV]] (primarily [[ATC code J05|J05]]) | ||
|listclass = hlist | |||
|state = {{{state<includeonly>|autocollapse</includeonly>}}} | |state = {{{state<includeonly>|autocollapse</includeonly>}}} | ||
| groupstyle = background:PowderBlue; | | groupstyle = background:PowderBlue; | ||
| group1 = [[Entry inhibitor|Entry/fusion inhibitors]] </br> ''([[Discovery and development of CCR5 receptor antagonists|Discovery & development]])'' | | group1 = [[Entry inhibitor|Entry/fusion inhibitors]] </br> ''([[Discovery and development of CCR5 receptor antagonists|Discovery & development]])'' | ||
| list1 = ''[[gp41]]'' ([[Enfuvirtide]]) | | list1 = | ||
* ''[[gp41]]'' ([[Enfuvirtide]]) | |||
* ''[[CCR5]]'' ([[Maraviroc]] | |||
* [[Vicriviroc]]<sup>†</sup>, [[Cenicriviroc]]<sup>†</sup>, [[PRO 140]]<sup>†</sup>) | |||
* ''[[CD4]]'' ([[Ibalizumab]]<sup>†</sup>) | |||
| group2 = [[Reverse transcriptase inhibitor|Reverse transcriptase<br/> inhibitors]] (RTIs) | | group2 = [[Reverse-transcriptase inhibitor|Reverse-transcriptase<br/> inhibitors]] (RTIs) | ||
| list2 = | | list2 = | ||
{{Navbox subgroup | {{Navbox subgroup | ||
| groupstyle = background:PowderBlue; | | groupstyle = background:PowderBlue; | ||
| group1 = [[Reverse transcriptase inhibitor|Nucleoside &<br/> | | group1 = [[Reverse transcriptase inhibitor|Nucleoside &<br/> nucleotide (NRTI)]] | ||
| list1 = ''[[Nucleoside analogue]]s/[[ | | list1 = | ||
* ''[[Nucleoside analogue]]s/[[Reverse transcriptase inhibitor#Nucleoside analog reverse transcriptase inhibitors .28NARTIs or NRTIs.29|NARTIs]]:'' [[Abacavir|Abacavir (ABC)]]°<sup>#</sup> | |||
* [[Emtricitabine|Emtricitabine (FTC)]]°<sup>#</sup> | |||
* [[Lamivudine|Lamivudine (3TC)]]°<sup>#</sup> | |||
* [[Didanosine|Didanosine (ddI)]]<sup>#</sup> | |||
* [[Zidovudine|Zidovudine (AZT)]]<sup>#</sup> | |||
* [[Apricitabine]]<sup>†</sup> | |||
* [[Stampidine]]<sup>†</sup> | |||
* [[Elvucitabine]]<sup>†</sup> | |||
* [[Racivir]]<sup>†</sup> | |||
* [[Amdoxovir]]<sup>†</sup> | |||
* [[Stavudine|Stavudine (d4T)]]<sup>#</sup> | |||
* [[Zalcitabine|Zalcitabine (ddC)]]<sup>◊</sup> | |||
* [[Festinavir]]<sup>†</sup> | |||
''[[Nucleotide analogue]]s/[[ | *''[[Nucleotide analogue]]s/[[Reverse transcriptase inhibitor#Nucleotide analog reverse transcriptase inhibitors .28NtARTIs or NtRTIs.29|NtRTI]]s:'' [[Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate (TDF)]]°<sup>#</sup> | ||
* [[Tenofovir alafenamide fumarate|Tenofovir alafenamide fumarate (TAF)]]<sup>†</sup> | |||
| group2 = [[ | | group2 = [[Reverse transcriptase inhibitor#Non-nucleoside reverse transcriptase inhibitors (NNRTIs)|Non-nucleoside (NNRTI)]]<br/>''([[Discovery and development of non-nucleoside reverse transcriptase inhibitors|Discovery & development]])'' | ||
| list2 = ''( | | list2 = | ||
* ''(1<sup>st</sup> generation)'' [[Efavirenz|Efavirenz (EFV)]]°<sup>#</sup> | |||
* [[Nevirapine|Nevirapine (NVP)]]<sup>#</sup> | |||
* [[Loviride]]<sup>◊</sup> | |||
* [[Delavirdine|Delavirdine (DLV)]]<sup>◊</sup> | |||
* </br> ''(2<sup>nd</sup> generation)'' ''[[diarylpyrimidines]]'' ([[Etravirine]] | |||
* [[Rilpivirine]]) | |||
* [[Lersivirine]]<sup>†</sup> | |||
}} | }} | ||
| group3 = [[Integrase inhibitor]]s | | group3 = [[Integrase inhibitor]]s | ||
| list3 = [[Raltegravir]] | | list3 = | ||
* [[Raltegravir]]° | |||
* [[Elvitegravir]] | |||
* [[Dolutegravir]]<sup>†</sup> | |||
* [[Globoidnan A]] (experimental) | |||
* [[MK-2048]]<sup>†</sup> | |||
* [[BI 224436]]<sup>†</sup> | |||
* [[GSK744]]<sup>†</sup> | |||
| group4 = [[Maturation inhibitor]]s | | group4 = [[Maturation inhibitor]]s | ||
| list4 = | | list4 = | ||
* [[Bevirimat]]<sup>†</sup> | |||
| group5 = [[Protease inhibitor (pharmacology)|Protease Inhibitors (PI)]]</br>''([[Discovery and development of HIV protease inhibitors|Discovery and development]])'' | | group5 = [[Protease inhibitor (pharmacology)|Protease Inhibitors (PI)]]</br>''([[Discovery and development of HIV protease inhibitors|Discovery and development]])'' | ||
| list5 = | | list5 = | ||
{{Navbox subgroup | |||
| groupstyle = background:PowderBlue; | |||
| group1 = 1<sup>st</sup> generation | |||
| list1 = | |||
* [[Fosamprenavir]]° | |||
* [[Lopinavir]]°<sup>#</sup> | |||
* [[Nelfinavir]]<sup>#</sup> | |||
* [[Ritonavir]]<sup>#</sup> | |||
* [[Saquinavir]]<sup>#</sup> | |||
* [[Amprenavir]]<sup>◊</sup> | |||
* [[Indinavir]]<sup>◊</sup><sup>#</sup> | |||
| group2 =2<sup>nd</sup> generation | |||
| list2 = | |||
* [[Atazanavir]]° | |||
* [[Darunavir]]° | |||
* [[Tipranavir]] | |||
}} | |||
| group6 = [[Fixed dose combination (antiretroviral)|Combined formulations]] | | group6 = [[Fixed-dose combination (antiretroviral)|Combined formulations]] | ||
| list6 = [[ | | list6 = | ||
* [[Lamivudine/zidovudine]] | |||
* [[Emtricitabine/tenofovir/efavirenz]] | |||
* [[Abacavir/lamivudine/zidovudine]] | |||
* [[Tenofovir/emtricitabine]] | |||
* [[Lopinavir/ritonavir]] | |||
* [[Abacavir/lamivudine]] | |||
* [[Emtricitabine/rilpivirine/tenofovir]] | |||
* [[Elvitegravir/cobicistat/emtricitabine/tenofovir]] | |||
| group7 = Experimental agents | | group7 = Experimental agents | ||
سطر 41: | سطر 103: | ||
| groupstyle = background:PowderBlue; | | groupstyle = background:PowderBlue; | ||
| group1 = [[ | | group1 = [[Antiviral drug#Uncoating inhibitor|Uncoating inhibitor]]s | ||
| list1 = [[TRIM5alpha]] (gene) | | list1 = | ||
* [[TRIM5alpha]] (gene) | |||
| group2 = [[Transcription (genetics)|Transcription inhibitor]]s | | group2 = [[Transcription (genetics)|Transcription inhibitor]]s | ||
| list2 = [[ | | list2 = | ||
* [[Tat (HIV)#Clinical significance|Tat antagonist]]s | |||
| group3 = [[ | | group3 = [[Antiviral drug#Translation .2F ribozymes|Translation inhibitor]]s | ||
| list3 = [[Trichosanthin]] | | list3 = | ||
* [[Trichosanthin]] | |||
| group4 = Other | | group4 = Other | ||
| list4 = [[Abzyme]] | | list4 = | ||
* [[Abzyme]] | |||
* [[Calanolide A]] | |||
* [[Ceragenin]] | |||
* [[Cyanovirin-N]] | |||
* [[Diarylpyrimidines]] | |||
* [[Epigallocatechin gallate|Epigallocatechin gallate (EGCG)]] | |||
* [[Foscarnet]] | |||
* [[Griffithsin]] | |||
* [[Hydroxycarbamide]] | |||
* [[Miltefosine]] | |||
* [[Portmanteau inhibitor]]s | |||
* [[Seliciclib]]<sup>†</sup> | |||
* [[Synergistic enhancer (antiretroviral)|Synergistic enhancer]]s | |||
* [[Tre recombinase]] | |||
* [[Zinc finger protein transcription factor]] | |||
* [[Error catastrophe#KP-1461|KP-1461]]<sup>†</sup> | |||
* [[Cobicistat]]<sup>†</sup> | |||
| group5 = Failed agents | | group5 = Failed agents | ||
| list5 = [[Dexelvucitabine]] | | list5 = | ||
* [[Dexelvucitabine]] | |||
* [[Capravirine]] | |||
* [[Emivirine]] | |||
* [[Lodenosine]] | |||
* [[Atevirdine]] | |||
* [[Brecanavir]] | |||
* [[Aplaviroc]] | |||
}} | }} | ||
|belowstyle = background: transparent; padding: 0px; | |||
|below = {{PharmNavFootnote}} °[[United States Department of Health and Human Services|DHHS]] preferred [[first-line treatment|first-line agent]]. <sup>◊</sup>Formerly or rarely used agent.<BR>{{Virus navs}} | |below = {{PharmNavFootnote}} °[[United States Department of Health and Human Services|DHHS]] preferred [[first-line treatment|first-line agent]]. <sup>◊</sup>Formerly or rarely used agent.<BR>{{Virus navs}} | ||
}}<noinclude> | }}<noinclude> | ||
[[تصنيف:جداول تصفح الأدوية | [[تصنيف:جداول تصفح الأدوية]] | ||
</noinclude> | </noinclude> |